Azaribine

CHEMBL515914 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

371.3 g/mol

LogP

-0.2

Phase

4

An antimetabolite that was used for psoriasis and polycythemia vera by interfering with pyrimidine synthesis, but it was withdrawn from use due to a significant risk of thromboembolic complications.

Peso molecular

371,3000 g/mol

LogP

-0,20

TPSA

150,00 Å²

Regla de cinco de Lipinski

Cumple

Mecanismo de acción

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O

InChI

InChI=1S/C14H17N3O9/c1-6(18)23-5-9-11(24-7(2)19)12(25-8(3)20)13(26-9)17-14(22)16-10(21)4-15-17/h4,9,11-13H,5H2,1-3H3,(H,16,21,22)/t9-,11-,12-,13-/m1/s1

Molecular Formula

C14H17N3O9

HBD / HBA

1 / 10

Enlaces Rotables

8

Átomos Pesados

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An antimetabolite that was used for psoriasis and polycythemia vera by interfering with pyrimidine synthesis, but it was withdrawn from use due to a significant risk of thromboembolic complications.

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Yes, Azaribine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL515914. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16574. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Azaribine en PillFYI

Estructura

Datos Rápidos

Fórmula: C14H17N3O9

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.